

```
SEQUENCE LISTING
110> Schenk, Dale B.
      Elan Pharmaceuticals
<120> Prevention and Treatment of Amyloidogenic Diseases
<130> 015270-005912US
<140> US 09/724,575
<141> 2000-11-28
<150> WO PCT/US00/25239
<151> 2000-06-01
<150> US 60/137,010
<151> 1999-06-01
<160> 34
<170> PatentIn Ver. 2.1
<210> 1
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:influenza
      hemagglutinin HA 307-319 universal T-cell epitope
<400> 1
Pro Lys Tyr Val Lys Gln Asn Thr Leu Lys Leu Ala Thr
<210> 2
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: PADRE universal
     T-cell epitope
<220>
<221> MOD RES
```

Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala

<210> 3 <211> 16 <212> PRT <213> Artificial Sequence

<223> Xaa = any amino acid

<220>

<222> (3)

RECEIVED TECHCEIVER 1800/2910

```
<223> Description of Artificial Sequence:malaria CS T3
      epitope universal T-cell epitope
<400> 3
Glu Lys Lys Ile Ala Lys Met Glu Lys Ala Ser Ser Val Phe Asn Val
<210> 4
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Hepatitis B
      surface antigen HBsAg 19-28 universal T-cell
      epitope
<400> 4
Phe Phe Leu Leu Thr Arg Ile Leu Thr Ile
<210> 5
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:heat shock
      protein 65 hsp65 153-171 universal T-cell epitope
<400> 5
Asp Gln Ser Ile Gly Asp Leu Ile Ala Glu Ala Met Asp Lys Val Gly
                                      10
Asn Glu Gly
<210> 6
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:bacillus
      Calmette-Guerin universal T-cell epitope
<400> 6
Gln Val His Phe Gln Pro Leu Pro Pro Ala Val Val Lys Leu
                                     10
 1
<210> 7
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:tetanus toxoid
```

TT 830-844 universal T-cell epitope

```
Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu
 1
                                      10
<210> 8
<211> 21
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:tetanus toxoid
      TT 947-967 universal T-cell epitope
<400> 8
Phe Asn Asn Phe Thr Val Ser Phe Trp Leu Arg Val Pro Lys Val Ser
                                     1.0
Ala Ser His Leu Glu
             20
<210> 9
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: HIV gp120 T1
      universal T-cell epitope
<400> 9
Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Lys Ala Met Tyr Ala
                                     10
 1
<210> 10
<211> 22
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: AN90549 (Abeta
      1-7/tetanus toxoid 830-844 in a MAP4
      configuration)
<400> 10
Asp Ala Glu Phe Arg His Asp Gln Tyr Ile Lys Ala Asn Ser Lys Phe
Ile Gly Ile Thr Glu Leu
<210> 11
<211> 28
<212> PRT
<213> Artificial Sequence
```

<223> Description of Artificial Sequence: AN90550 (Abeta 1-7/tetanus toxoid 947-967 in a MAP4 configuration) Asp Ala Glu Phe Arg His Asp Phe Asn Asn Phe Thr Val Ser Phe Trp 10 1 Leu Arg Val Pro Lys Val Ser Ala Ser His Leu Glu 2.0 <210> 12 <211> 43 <212> PRT <213> Artificial Sequence <223> Description of Artificial Sequence: AN 90542 (Abeta 1-7/tetanus toxoid 830-844 + 947-967 in a linear configuration) Asp Ala Glu Phe Arg His Asp Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu Phe Asn Asn Phe Thr Val Ser Phe Trp Leu 25 20 Arg Val Pro Lys Val Ser Ala Ser His Leu Glu 35 <210> 13 <211> 22 <212> PRT <213> Artificial Sequence <223> Description of Artificial Sequence: AN 90576 (Abeta 3-9/tetanus toxoid 830-844 in a MAP4 configuration) Glu Phe Arg His Asp Ser Gly Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu 20 <210> 14 <211> 20 <212> PRT <213> Artificial Sequence <223> Description of Artificial Sequence: AN90562 (Abeta <220> 1-7/peptide on linear conformmation)

<220> <221> MOD RES <222> (3) <223> Xaa = any amino acid <400> 14 Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Asp Ala Glu Phe Arg His Asp <210> 15 <211> 34 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: AN90543 (Abeta 1-7 X 3/peptide in linear conformation) <220> <221> MOD RES <222> (24) <223> Xaa = any amino acid <400> 15 Asp Ala Glu Phe Arg His Asp Asp Ala Glu Phe Arg His Asp Asp Ala Glu Phe Arg His Asp Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala 25 Ala Ala <210> 16 <211> 34 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: fusion protein with Abeta immunogenic epitope <220> <221> MOD RES <222> (3) <223> Xaa = any amino acid <400> 16 Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala Asp Ala Glu Phe Arg His Asp Asp Ala Glu Phe Arg His Asp Asp Ala Glu Phe Arg

5

His Asp

```
<210> 17
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: fusion protein
      with Abeta immunogenic epitope
<220>
<221> MOD_ RES
<222> (10)
<223> Xaa = any amino acid
<400> 17
Asp Ala Glu Phe Arg His Asp Ala Lys Xaa Val Ala Ala Trp Thr Leu
Lys Ala Ala Ala
             20
<210> 18
<211> 24
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: fusion protein
      with Abeta immunogenic epitope
<400> 18
Asp Ala Glu Phe Arg His Asp Ile Ser Gln Ala Val His Ala Ala His
                                      10
Ala Glu Ile Asn Glu Ala Gly Arg
<210> 19
<211> 24
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: fusion protein
      with Abeta immunogenic epitope
<400> 19
Phe Arg His Asp Ser Gly Tyr Ile Ser Gln Ala Val His Ala Ala His
                  5
  1
Ala Glu Ile Asn Glu Ala Gly Arg
             20
<210> 20
<211> 24
<212> PRT
```

<213> Artificial Sequence <220> <223> Description of Artificial Sequence: fusion protein with Abeta immunogenic epitope <400> 20 Glu Phe Arg His Asp Ser Gly Ile Ser Gln Ala Val His Ala Ala His Ala Glu Ile Asn Glu Ala Gly Arg <210> 21 <211> 34 <212> PRT <213> Artificial Sequence <223> Description of Artificial Sequence: fusion protein with Abeta immunogenic epitope <400> 21 Pro Lys Tyr Val Lys Gln Asn Thr Leu Lys Leu Ala Thr Asp Ala Glu Phe Arg His Asp Asp Ala Glu Phe Arg His Asp Asp Ala Glu Phe Arg His Asp <210> 22 <211> 27 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: fusion protein with Abeta immunogenic epitope Asp Ala Glu Phe Arg His Asp Pro Lys Tyr Val Lys Gln Asn Thr Leu Lys Leu Ala Thr Asp Ala Glu Phe Arg His Asp <210> 23 <211> 34 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: fusion protein with Abeta immunogenic epitope

7

<400> 23

Asp Ala Glu Phe Arg His Asp Asp Ala Glu Phe Arg His Asp Asp Ala Glu Phe Arg His Asp Pro Lys Tyr Val Lys Gln Asn Thr Leu Lys Leu Ala Thr <210> 24 <211> 27 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: fusion protein with Abeta immunogenic epitope <400> 24 Asp Ala Glu Phe Arg His Asp Asp Ala Glu Phe Arg His Asp Pro Lys Tyr Val Lys Gln Asn Thr Leu Lys Leu Ala Thr <210> 25 <211> 136 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: fusion protein with Abeta immunogenic epitope <400> 25 Asp Ala Glu Phe Arg His Asp Pro Lys Tyr Val Lys Gln Asn Thr Leu Lys Leu Ala Thr Glu Lys Lys Ile Ala Lys Met Glu Lys Ala Ser Ser Val Phe Asn Val Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu Phe Asn Asn Phe Thr Val Ser Phe Trp Leu Arg Val Pro Lys Val Ser Ala Ser His Leu Glu Asp Ala Glu Phe Arg His Asp Asp

Ala Glu Phe Arg His Asp Asp Ala Glu Phe Arg His Asp Asp Ala Glu 90 95

Phe Arg His Asp Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile 100 105 110

Thr Glu Leu Phe Asn Asn Phe Thr Val Ser Phe Trp Leu Arg Val Pro 115 120 125

Lys Val Ser Ala Ser His Leu Glu 130 <210> 26 <211> 44 <212> PRT <213> Artificial Sequence <223> Description of Artificial Sequence: fusion protein with Abeta immunogenic epitope <400> 26 Asp Ala Glu Phe Arg His Asp Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu Cys Phe Asn Asn Phe Thr Val Ser Phe Trp Leu Arg Val Pro Lys Val Ser Ala Ser His Leu Glu <210> 27 <211> 51 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: fusion protein with Abeta immunogenic epitope Asp Ala Glu Phe Arg His Asp Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu Cys Phe Asn Asn Phe Thr Val Ser Phe Trp 25 Leu Arg Val Pro Lys Val Ser Ala Ser His Leu Glu Asp Ala Glu Phe 40 Arg His Asp 50 <210> 28 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: fusion protein with Abeta immunogenic epitope on a 2 branched

Asp Ala Glu Phe Arg His Asp Gln Tyr Ile Lys Ala Asn Ser Lys Phe

resin of Lys-Gly-Cys

<400> 28

Ile Gly Ile Thr Glu Leu

```
20
<210> 29
<211> 26
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence:synuclein
      fusion protein in MAP-4 configuration
<400> 29
Glu Gln Val Thr Asn Val Gly Gly Ala Ile Ser Gln Ala Val His Ala
Ala His Ala Glu Ile Asn Glu Ala Gly Arg
<210> 30
<213> Artificial Sequence
<220>
      peptide with Cys added
```

<211> 13 <212> PRT

<223> Description of Artificial Sequence: Abeta 1-12

10

<400> 30 Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val Cys 5

<210> 31 <211> 6 <212> PRT <213> Artificial Sequence

<220> <223> Description of Artificial Sequence: Abeta 1-5 peptide with Cys added

<400> 31 Asp Ala Glu Phe Arg Cys 5 1

<210> 32 <211> 12 <212> PRT <213> Artificial Sequence <220>

<223> Description of Artificial Sequence: Abeta 33-42 peptide with Cys added

<220> <221> MOD_RES <222> (2)

```
<223> Xaa = amino-heptanoic acid
<400> 32
Cys Xaa Gly Leu Met Val Gly Gly Val Val Ile Ala
                 5
<210> 33
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Abeta 13-28
      peptide with Cys added
<220>
<221> MOD RES
<222> (1)
<223> Xaa = acetyl-asparagine
<400> 33
Xaa His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser
Asn Lys Gly Gly Cys
<210> 34
<211> 42
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Abeta 42
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
                                 25
             20
Gly Leu Met Val Gly Gly Val Val Ile Ala
```

40

35